Botulism Market

Demand for botulism treatment will increase through 2036, with heptavalent botulinium antitoxin at 37.9% of the drug type segment in 2026, driven by established clinical protocols and sustained procurement from hospital systems. The market was valued at USD 8.90 billion in 2025 and is expected to be worth USD 18.16 billion by 2036.